Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
A Phase 1/2 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Sponsor: Cybrexa Therapeutics
Listed as NCT04902872, this PHASE1/PHASE2 trial focuses on Appendix Cancer and Breast Cancer and remains ongoing. Sponsored by Cybrexa Therapeutics, it has been updated 8 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Jun 2025 — Present [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Feb 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
May 2023 — Feb 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2022 — May 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2021 — Jun 2022 [monthly]
Recruiting PHASE1_PHASE2
First recorded
May 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cybrexa Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .